Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | DT2216 |
Trade Name | |
Synonyms | DT 2216|DT-2216|PROTAC Bcl-XL Deagrader DT2216 |
Drug Descriptions |
DT2216 is a small molecule proteolysis-targeted chimera (PROTAC) that binds to BCL-XL and targets it for degradation, potentially resulting in decreased tumor growth (PMID: 31792461, PMID: 32677976). |
DrugClasses | BCL-XL inhibitor 14 |
CAS Registry Number | NA |
NCIT ID | C179922 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Asparaginase + Dexamethasone + DT2216 + Vincristine Sulfate | Asparaginase DT2216 Dexamethasone Vincristine Sulfate | 0 | 0 |
Docetaxel + DT2216 | DT2216 Docetaxel | 0 | 0 |
Doxorubicin + DT2216 | DT2216 Doxorubicin | 0 | 0 |
DT2216 | DT2216 | 0 | 1 |
DT2216 + S63845 | DT2216 S63845 | 0 | 0 |
DT2216 + Sotorasib | DT2216 Sotorasib | 0 | 0 |
DT2216 + Venetoclax | DT2216 Venetoclax | 0 | 0 |
DT2216 + Vincristine Sulfate | DT2216 Vincristine Sulfate | 0 | 0 |